A Wolf in Sheep’s Clothing: The Government’s Latest Stand Against Patient Kickbacks Disguised as Charity

The U.S. Department of Justice (DOJ) is deeply committed to combating drug companies’ pervasive practice of disguising patient kickbacks as charity. Most recently, Boston-based prosecutors reached a $51 million settlement with Swiss pharmaceutical giant Novartis, resolving allegations that Novartis coordinated with charitable foundations to steer Medicare patients to its drugs and away from competitors’ cheaper alternatives. The “charitable” foundations doled money out to patients to cover their Medicare copays for Novartis drugs, but not for those of competing companies. 

The government treats these kinds of “charitable” contributions as patient kickbacks, and thus a violation of the Anti-kickback Statute, which prohibits payments to patients that might alter their choices, because they eliminate regular market forces that drive patients to use cheaper drugs, drive their doctors to prescribe them, and drive pharmaceutical companies to develop them. If, through these “charitable” contributions, expensive drugs wind up costing them nothing (or very little), patients will continue to use the expensive drugs, causing Medicare to be improperly billed thousands.

Last month, the DOJ filed another False Claims Act case, this time against the pharmaceutical company Regeneron, alleging similar conduct: paying kickbacks in the form of charitable co-pay waivers to steer patients to the company’s macular degeneration drug, Eylea. The Boston U.S. Attorney’s Office has collected nearly a billion dollars pursuing these cases against many giants in the pharmaceutical industry, including PfizerUnited TherapeuticsAmgenAstellasAlexion, Actelion, Jazz, and Sanofi-Aventis.

Big pharma is, of course, free to make legitimate donations to charity. However, the potential illegality arises when those donations are meant to boost sales of the donor’s products at the expense of competitors and the Medicare Trust Fund, which is exactly what was alleged in the Novartis case. Novartis allegedly timed its donations to be available exactly, and only, when it told patients to contact these foundations. Regeneron executives allegedly ordered substantial analyses evaluating the return on investment of their “charitable,” donations and did what they could to boost that number.

Like the panel of drugs Novartis was promoting, Regeneron’s Eylea is an expensive drug. It generally costs about $10,000 a year, per patient, and since 2013, Medicare has spent $11 billion on it. Regeneron set Eylea’s dose price at $1,850, while alternatives like Avastin run as low as $55 per dose.

While the Novartis and Regeneron cases were brought directly by the government, several of the other cases were initiated by whistleblowers. Because relationships between drug companies and charities are often confusing and opaque, whistleblowers are essential to bringing frauds like these to light, saving the Medicare program, and American taxpayers, astounding sums of money. 

Facebook
Twitter
LinkedIn

Mary Inman, Esq.

Mary Inman is a partner and co-founder of Whistleblower Partners LLP, a law firm dedicated to representing whistleblowers under the various U.S. whistleblower reward programs. Mary and her colleagues have pioneered a series of successful whistleblower cases against prominent health insurers, hospitals, provider groups, and vendors under the False Claims Act alleging manipulation of the risk scores of Medicare Advantage patients. Mary is a recognized expert and frequent author, commentator, and speaker on frauds in the healthcare industry, particularly those exposed by whistleblowers. Mary is a member of the RACmonitor editorial board and a popular panelist on Monitor Monday.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

I050825

Mastering ICD-10-CM Coding for Diabetes and it’s Complications: Avoiding Denials & Ensuring Compliance

Struggling with ICD-10-CM coding for diabetes and complications? This expert-led webcast clarifies complex combination codes, documentation gaps, and sequencing rules to reduce denials and ensure compliance. Dr. Angela Comfort will provide actionable strategies to accurately link diabetes to complications, improve provider documentation, and optimize reimbursement—helping coders, CDI specialists, and HIM leaders minimize audit risks and strengthen revenue integrity. Don’t miss this chance to master diabetes coding with real-world case studies, key takeaways, and live Q&A!

May 8, 2025

Trending News

Featured Webcasts

Navigating the 3-Day & 1-Day Payment Window: Compliance, Billing, and Revenue Protection

Navigating the 3-Day & 1-Day Payment Window: Compliance, Billing, and Revenue Protection

Struggling with CMS’s 3-Day Payment Window? Join compliance expert Michael G. Calahan, PA, MBA, CCO, to master billing restrictions for pre-admission and inter-facility services. Learn how to avoid audit risks, optimize revenue cycle workflows, and ensure compliance across departments. Critical for C-suite leaders, providers, coders, revenue cycle teams, and compliance teams—this webcast delivers actionable strategies to protect reimbursements and meet federal regulations.

May 15, 2025
Audit-Proof Your Wound Care Procedures: Expert Insights on Compliance and Risk Mitigation

Audit-Proof Your Wound Care Procedures: Expert Insights on Compliance and Risk Mitigation

Providers face increasing Medicare audits when using skin substitute grafts, leaving many unprepared for claim denials and financial liabilities. Join veteran healthcare attorney Andrew B. Wachler, Esq., in this essential webcast and master the Medicare audit process, learn best practices for compliant billing and documentation, and mitigate fraud and abuse risks. With actionable insights and a live Q&A session, you’ll gain the tools to defend your practice and ensure compliance in this rapidly evolving landscape.

April 17, 2025
Utilization Review Essentials: What Every Professional Needs to Know About Medicare

Utilization Review Essentials: What Every Professional Needs to Know About Medicare

Dr. Ronald Hirsch dives into the basics of Medicare for clinicians to be successful as utilization review professionals. He’ll break down what Medicare does and doesn’t pay for, what services it provides and how hospitals get paid for providing those services – including both inpatient and outpatient. Learn how claims are prepared and how much patients must pay for their care. By attending our webcast, you will gain a new understanding of these issues and be better equipped to talk to patients, to their medical staff, and to their administrative team.

March 20, 2025

Rethinking Observation Metrics: Standardizing Data for Better Outcomes

Hospitals face growing challenges in measuring observation metrics due to inconsistencies in classification, payer policies, and benchmarking practices. Join Tiffany Ferguson, LMSW, CMAC, ACM, and Anuja Mohla, DO, FACP, MBA, ACPA-C, CHCQM-PHYADV as they provide critical insights into refining observation metrics. This webcast will address key issues affecting observation data integrity and offer strategies for improving consistency in reporting. You will learn how to define meaningful metrics, clarify commonly misinterpreted terms, and apply best practices for benchmarking, and gain actionable strategies to enhance observation data reliability, mitigate financial risk, and drive better decision-making.

February 25, 2025

Trending News

Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24